ALZpath, Siemens Healthineers Partner on Blood-Based Alzheimer’s Testing
Licensing agreement will integrate ALZpath's pTau217 antibody into Siemens' Atellica analyzer test menu for IVD Alzheimer's diagnostics.
Category: Dementias & Alzheimer’s
Dementias & Alzheimer’s
Latest
Dementias & Alzheimer’s
Latest
FDA Clears Blood Test for Alzheimer’s Assessment in Primary Care
The test measures phosphorylated Tau 181 protein to help rule out Alzheimer's-related amyloid pathology in patients 55 and older.
Dementias & Alzheimer’s
Latest
Blood-Based Biomarker Testing for Alzheimer’s Gets Formal Guidance
The Alzheimer's Association released its first clinical practice guideline on the use of blood-based biomarker tests.
Simoa Technology Platform Expands Into New Market
Quanterix Corporation’s HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration in South Korea.
Read More
Blood Test for Alzheimer’s Cleared by FDA
An FDA-cleared blood test that measures key Alzheimer’s disease biomarkers is a less invasive, more accurate method to diagnose the condition.
Read More
Test Detects P-SYN in Skin Biopsies of Patients with iRBD
Summary: CND Life Sciences has released baseline results from its NIH-funded Syn-Sleep Study,...
Read More
NULISAseq CNS Disease Panel 120 Expanded with Blood-Based Brain-Derived pTau Assays
Alamar Biosciences has expanded its NULISAseq CNS Disease Panel 120 to include highly sensitive, blood-based assays.
Read More
Astrocytes Play Key Role in Alzheimer’s Disease
Researchers have identified the key enzyme causing Alzheimer’s disease by linking it to excessive GABA production in reactive astrocytes.
Read More
Blood Test Provides Accurate Results for Alzheimer’s Detection
A large international study found that a simpler blood test method using plasma P-tau217 can accurately detect Alzheimer’s disease.
Read More
Parkinson’s Disease Needs Improved Diagnostic Processes
A study found that up to 17.7% of initial Parkinson’s disease diagnoses are later revised, highlighting the challenges of its diagnosis.
Read More
Blood-Based Biomarker Test Accelerates Path to Diagnosis of Alzheimer’s Disease
Labcorp has launched a nationwide blood-based biomarker test, the pTau-217/Beta Amyloid 42 Ratio, to aid in diagnosing Alzheimer’s disease.
Read More
pTau217 Antibody Demonstrates High Rate of Reliability and Scalability
ALZpath, Inc. announced that it presented data from evaluations of its proprietary pTau217 antibody for blood-based Alzheimer’s diagnostics.
Read More
Alzheimer’s Disease Diagnosed with Highly Accurate Blood Test
A new blood test for Alzheimer’s disease not only aids in diagnosis but also helps determine the disease’s progression.
Read More
Video Game Test May Be as Effective as Blood Tests for Alzheimer’s Early Detection
A video game test may help detect Alzheimer’s years before symptoms appear, offering a non-invasive alternative to blood tests.
Read More
IL-12 Is the Messenger Fueling Alzheimer’s
Microglia can transition from protective to harmful with age, producing inflammatory messengers like IL-12, which accelerates Alzheimer’s.
Read More
Blood Test May Be Means for Early Detection of Dementia
A blood test originally developed for Alzheimer’s can help predict dementia in patients with iRBD years before symptoms appear.
Read More
P-tau not as Disease-Specific for Alzheimer’s as Previously Thought
The detection of p-tau proteins in the blood for early Alzheimer’s disease (AD) diagnosis is less specific than previously believed.
Read More
Study Aims to Identify New Auditory Biomarkers
The SAPHIR study aims to develop auditory biomarkers for early detection and improved disease management related to cognitive decline.
Read More